You are here

Board of Directors

Angiochem's Board of Directors is a distinguished group of industry leaders who oversee the activities of the company.

John Huss, Executive Chairman 

Mr Huss has more than 25 years of global pharmaceutical experience. He spent 20 years with Merck & Co., Roche and Sanofi on the pharmaceutical side of the business, before moving to biotechnology.  He served as CEO, President and Director of Theratechnologies and is currently Founder, President and CEO of H&P Labs Inc.  He is also Vice-President, member of the Executive Committee and a Director at BioQuebec.

Robert Blain, Co-CEO, Groupe Lune Rouge

Mr Blain has more than 20 years in the international entertainment industry, is Co-CEO of Groupe Lune Rouge Inc., a company that develops projects and invests in different funds with a focus on Technology, Life sciences, Entertainment and Real Estate. As well as taking care of the Family office of Mr. Guy Laliberté, Mr. Blain also acts as an investment manager in Lune Rouge. Since 2007, Mr. Blain has been an administrator and treasurer for One Drop Foundation which aims to fight poverty by supporting access to water worldwide. He also sits as the Treasurer on Sainte-Justine UHC Foundation, one of the most important pediatric centers in North America.

Martin Godbout, O.C., Ph.D.

Dr. Godbout was the President and Chief Executive Officer of Genome Canada from April 2000 to October 2009, and before that he was Senior Vice President at BioCapital and President and General Manager of Société Innovatech Québec. Between 1996 and 2004, he was a member of the Board of the “Conseil de la Science et de la Technologie du Québec” and he has been an Advisory member of several Canadian biopharmaceutical venture firms such as SGF Santé, Société Innovatech du Grand Montréal and Royal Bank Ventures Inc. In 2005, Dr. Godbout was appointed Officer of the Order of Canada. He was also awarded the Grand Prix de Recherche from the Québec Foundation for Mental Disorders for his previous work on Alzheimer’s disease in 1991 and the “Prix Summa” in 1994 from the Faculty of Science and Engineering of Université Laval. In 1994, he also founded BioContact Québec which has become one of the most important biopharmaceutical symposiums in North America. He holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular Endocrinology from Université Laval. In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world.”